• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24104 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofersen (SOD1-associated amyotrophic lateral sclerosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aztreonam/avibactam (bacterial infections, several therapeutic indications) – Assessment according to §35a (para. 1c) Social Code Book V]
2024     NIHR Health Technology Assessment programme Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT
2024     NIHR Health Services and Delivery Research programme Signposting services for people with health and care needs: a rapid realist review
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Generalized anxiety disorder - Do apps help people affected cope with their condition?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [rADAMTS13 (congenital thrombotic thrombocytopenic purpura) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     NIHR Health Technology Assessment programme Cerclage suture type to prevent pregnancy loss in women requiring a vaginal cervical cerclage: the C-STICH RCT
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cataract: Does surgery with the femtosecond laser offer advantages over other procedures for people affected?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46]
2024     NIHR Health and Social Care Delivery Program Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (hidradenitis suppurativa) - Addendum to Project A24-64]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     Agency for Care Effectiveness (ACE) PCSK9 inhibitors for treating hypercholesterolaemia
2024     NIHR Health and Social Care Delivery Program Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – addendum to Project A24-66]
2024     NIHR Health and Social Care Delivery Program The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation
2024     NIHR Health and Social Care Delivery Program Health and wellbeing of survivors of sexual violence and abuse attending sexual assault referral centres in England: the MESARCH mixed-methods evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cefepime/enmetazobactam (bacterial infections, several therapeutic indications) – Addendum to Project G24-15]
2024     Agency for Care Effectiveness (ACE) Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer
2024     NIHR Health and Social Care Delivery Program Feasibility of in-home monitoring for people with glaucoma: the I-TRAC mixed-methods study
2024     NIHR Health and Social Care Delivery Program Effects of computerised clinical decision support systems (CDSS) on nursing and allied health professional performance and patient outcomes: a systematic review of experimental and observational studies
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Methods for determining the extent of added benefit - empirical data from dossier assessments]
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating persistent, recurrent, or metastatic cervical cancer
2024     NIHR Health and Social Care Delivery Program Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
2024     Haute Autorite de sante (HAS) [Evaluation of high-intensity focused ultrasound (HIFU) for the treatment of symptomatic uterine fibroids]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – assessment according to §137h Social Code Book (SGB) V]
2024     Agency for Care Effectiveness (ACE) Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration
2024     NIHR Health and Social Care Delivery Program Real-time ultrasound elastography in the diagnosis of newly identified thyroid nodules in adults: the ElaTION RCT
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – addendum to project H23-03]
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
2024     NIHR Health and Social Care Delivery Program Development and validation of prediction models for fetal growth restriction and birthweight: an individual participant data meta-analysis
2024     Haute Autorite de sante (HAS) [Next generation sequencing gene panel for gastrointestinal stromal tumour care]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: quantification of antipsychotics in serum using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS)]
2024     Agency for Care Effectiveness (ACE) Pembrolizumab for the adjuvant treatment of renal cell carcinoma
2024     NIHR Health and Social Care Delivery Program Community-based complex interventions to sustain independence in older people, stratified by frailty: a systematic review and network meta-analysis
2024     NIHR Health Technology Assessment programme Strategies for older people living in care homes to prevent urinary tract infection: the StOP UTI realist synthesis
2024     Agency for Care Effectiveness (ACE) Tafamidis for treating transthyretin amyloid cardiomyopathy
2024     NIHR Health and Social Care Delivery Program Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice : close follow-up practices for people at risk of suicide after hospital discharge: challenges and possible solutions]
2024     NIHR Health Services and Delivery Research programme Strengthening open disclosure in maternity services in the English NHS: the DISCERN realist evaluation study
2024     Agency for Care Effectiveness (ACE) Abrocitinib, baricitinib, upadacitinib and dupilumab for treating atopic dermatitis
2024     NIHR Health and Social Care Delivery Program Artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer: an evidence synthesis early value assessment
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: determination of blood titanium levels]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to managing people with colorectal cancer]
2024     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
2024     NIHR Health and Social Care Delivery Program Hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery for people with peritoneal metastases: a systematic review and cost-effectiveness analysis
2024     Ontario Health Sucrose octasulfate-impregnated dressings for adults with difficult-to-heal noninfected diabetic foot ulcers and difficult-to-heal noninfected venous leg ulcers
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: medical imaging of the head]
2024     NIHR Health and Social Care Delivery Program Behaviour change intervention (education and text) to prevent dental caries in secondary school pupils: BRIGHT RCT, process and economic evaluation
2024     Ontario Health Fractional exhaled nitric oxide testing for the diagnosis and management of asthma
2024     NIHR Health and Social Care Delivery Program Impact of frailty in older people on health care demand: simulation modelling of population dynamics to inform service planning
2024     NIHR Health and Social Care Delivery Program Chair-based yoga programme for older adults with multimorbidity: RCT with embedded economic and process evaluations
2024     Ontario Health Level 2 polysomnography for the diagnosis of sleep disorders
2024     NIHR Health Technology Assessment programme Cervical ripening at home or in hospital during induction of labour: the CHOICE prospective cohort study, process evaluation and economic analysis
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Chronic graft-versus-host disease; assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health and Social Care Delivery Program The UK resuscitative endovascular balloon occlusion of the aorta in trauma patients with life-threatening torso haemorrhage: the (UK-REBOA) multicentre RCT
2024     Ontario Health Pelvic floor muscle training for stress urinary incontinence, fecal incontinence, and pelvic organ prolapse
2024     NIHR Health Services and Delivery Research programme Clinical and cost-effectiveness of first contact physiotherapy for musculoskeletal disorders in primary care: the FRONTIER, mixed method realist evaluation
2024     NIHR Health and Social Care Delivery Program Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT
2024     Haute Autorite de sante (HAS) [Targeted next generation sequencing gene panel in the medical management of chronic lymphocytic leukemia]
2024     NIHR Health Services and Delivery Research programme A model of occupational stress to assess impact of COVID-19 on critical care and redeployed nurses: a mixed-methods study
2024     NIHR Health and Social Care Delivery Program Improving the integration of care for trans adults: ICTA a mixed-methods study
2024     WorkSafeBC Efficacy/effectiveness of prolotherapy in treating wrist sprain/strain or repetitive strain injury (RSI)
2024     NIHR Health Technology Assessment programme Energetic activity for depression in young people aged 13–17 years: the READY feasibility RCT
2024     NIHR Health and Social Care Delivery Program Understanding and using experiences of social care to guide service improvements: translating a co-design approach from health to social care
2024     WorkSafeBC Causal association in developing breast cancer among female firefighters
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood cortisol and dexamethasone measurements using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the context of a dexamethasone suppression test]
2024     Agency for Care Effectiveness (ACE) Wingspan stent system for intracranial atherosclerotic stenosis
2024     NIHR Health Technology Assessment programme Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
2024     NIHR Health and Social Care Delivery Program The Resilience Hub approach for addressing mental health of health and social care workers during the COVID-19 pandemic: a mixed-methods evaluation
2024     WorkSafeBC Causal association on the development of trigeminal neuralgia post covid-19 vaccine
2024     HTA Region Stockholm [Benefits and harms of intra-articular corticosteroid injections for hip osteoarthritis]
2024     Agency for Care Effectiveness (ACE) Cochlear implants for children with single-sided deafness
2024     NIHR Health Technology Assessment programme Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis
2024     Penn Medicine Center for Evidence-based Practice (CEP) Urinary catheterization for epidural anesthesia in obstetrics
2024     WorkSafeBC Efficacy/effectiveness of brain mapping in treating concussions
2024     HTA Region Stockholm [Effectiveness and safety of intense pulsed light therapy for dry eye symptoms due to meibomian gland dysfunction]
2024     NIHR Health Technology Assessment programme A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
2024     NIHR Health and Social Care Delivery Program Interventions to minimise hospital winter pressures related to discharge planning and integrated care: a rapid mapping review of UK evidence
2024     WorkSafeBC Effectiveness of prolotherapy in shoulder labral tears
2024     National Institute for Health and Care Excellence (NICE) Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance 1026
2024     NIHR Health Technology Assessment programme Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study
2024     WorkSafeBC Causal association between firefighting and pulmonary fibrosis
2024     National Institute for Health and Care Excellence (NICE) Ublituximab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 1025
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lebrikizumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD individual patient data meta-analysis and systematic review
2024     NIHR Health and Social Care Delivery Program Women’s Health Hubs: a rapid mixed-methods evaluation
2024     WorkSafeBC Causal association between soft tissue injury/trauma and aggravation of CRPS
2024     National Institute for Health and Care Excellence (NICE) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. NICE technology appraisal guidance 1023
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: integrating innovations into social and health services systems]
2024     NIHR Health and Social Care Delivery Program Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT
2024     WorkSafeBC Efficacy/effectiveness of Cryoderm Cooling Gel®/Ligament Restore Supplement in treating lumbar sprain/strain
2024     National Institute for Health and Care Excellence (NICE) Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal). NICE technology appraisal guidance 1024
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V]
2024     NIHR Health and Social Care Delivery Program Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model
2024     WorkSafeBC Effectiveness of extra corporeal shockwave therapy (ESWT) in treating shoulder labral tears
2024     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021